Two U.S. senators urged GlaxoSmithKline to do more about the ongoing shortage of Shingrix.
Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.
Here is some other vaccine news of note for the week.
Officials have vaccinated about 3,200 individuals in the Democratic Republic of Congo in response to a deadly outbreak.
GlaxoSmithKline's Shingrix is exceeding sales expectations, and high demand has led the company to implement order limits.
Patients might be hesitant to return for their second Shingrix dose if they experience side effects, according to doctors.
After reporting phase 2b results for FLU-v, SEEK Group CEO Gregory Stoloff said the program is ready for phase 3.
Merck is seeking FDA approval to expand Gardasil 9's use in women and men ages 27 to 45.
_5.jpg/6277208708_7e6607d601_b_0 (1)_5.jpg?TocNSHJyZJZbcBVK1h8swJrpPHrAEr53&itok=bDjvXdNf "non")
